Navigation Links
Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Date:9/10/2007

-R7128 Demonstrates Safety and Tolerability with No Clinically Significant

Adverse Events-

-Conference Call Scheduled for 8:30AM (ET) Today-

PRINCETON, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) is presenting safety, tolerability, pharmacokinetic and food effect data following single ascending doses of R7128 at the 14th International Symposium on Hepatitis C Virus and Related Viruses being held from September 9-13, 2007 in Glasgow, Scotland. R7128 is a prodrug of PSI- 6130, an oral cytidine nucleoside analog polymerase inhibitor of hepatitis C virus (HCV) that is being developed through Pharmasset's collaboration with Roche. The poster presentation from the conference is available in the "Events and Presentations" section of the Investor Center on Pharmasset's website at http://www.pharmasset.com.

The Phase 1 single ascending dose study of R7128 was designed to assess the safety, tolerability and pharmacokinetics of R7128 following single ascending doses under fasting conditions. The secondary objective of this study was to explore the effect of food on the pharmacokinetics of R7128. Single oral doses of R7128 were administered to 46 healthy volunteers in five sequential dose groups (500 mg, 1500 mg, 4500 mg, 6000 mg, and 9000 mg) and one food effect group (1500 mg). There were 8 subjects per sequential dose group (6 active, 2 placebo) and 6 subjects in the food effect group (all active).

Nineteen adverse events (AEs) were reported during the study, including headache, sunburn, sore throat and nasal congestion. All AEs were mild to moderate, none were related to dose and no
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmasset Presents Clevudine and Racivir Data at the International HIV Drug Resistance Workshop
2. Pharmasset Announces Clevudine and Hepatitis C Presentations at EASL
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... WORCESTER, Mass. and TORONTO ... www.generex.com ) (OTCBB: GNBT) today announced three presentations demonstrating ... developed by its wholly-owned subsidiary, Antigen Express, Inc. ( ... annual meeting of the American Society of Clinical Oncology ... from May 31 through June 4, 2013. ...
(Date:5/22/2013)... 2013  Grifols, a global healthcare company based in ... a study demonstrating that a higher dose of PROLASTIN ... of the alpha 1 protein in patients with ... considered within the normal range for healthy individuals. AAT ... levels of the alpha 1 proteinase inhibitor (A1PI) ...
(Date:5/22/2013)... LAKES, N.J. , May 22, 2013  BD ... a leading global medical technology company, announced today the ... is BD,s fifth Sustainability Report and it continues to ... "We believe the principles of shared ... and addressing healthcare challenges of societies — are fundamental ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4BD Issues 2012 Sustainability Report 2BD Issues 2012 Sustainability Report 3
... Accuray Incorporated (Nasdaq: ARAY ) ... announced acquisition of TomoTherapy Incorporated (Nasdaq: TOMO). The ... best-in-class technologies to fight cancer.  The combined company ... leading-edge treatment solutions that revolve around the patient. ...
... 13, 2011 Guidelines that reduce the use of mechanical ... of respiratory support can profoundly affect those children,s outcomes while ... researchers at Children,s Hospital Boston. The team, ... Medicine at Children,s Hospital Boston and the Neonatal Intensive Care ...
Cached Medicine Technology:Accuray Successfully Completes Acquisition of TomoTherapy 2Accuray Successfully Completes Acquisition of TomoTherapy 3Accuray Successfully Completes Acquisition of TomoTherapy 4Guidelines for Ventilator Use Help Premature Infants Breathe Easier 2Guidelines for Ventilator Use Help Premature Infants Breathe Easier 3
(Date:5/22/2013)... May 22, 2013 Nearly 50,000 veterans ... (BVA) in fiscal year 2012, with even more—54,033—expected by ... longer for a decision as the agency reports reduced ... provides veterans disability appeal services. The BVA ... Affairs. , Although the BVA received 49,611 cases in ...
(Date:5/22/2013)... A new study shows there is a gender ... American young children one that does not appear ... United States, girls had higher levels of self-regulation than ... their behavior and impulses, follow directions, and persist on ... and college completion, in past studies by Oregon State ...
(Date:5/22/2013)... 22, 2013 Successful Therapy for ... O’Laughlin Psychotherapy in the Silver Lake community of ... ages as progression to existing Parents and Couples ... into parenting therapy has always been suggested, but ... Psychotherapy now specializes in all aspects of ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Diversity Focus ... Handicap This! The performance promotes awareness that physical ... The Handicap This! performance will be held Friday, June ... School auditorium. Tickets for Handicap This! can be ... helps audiences measure the level to which their mind ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Today, Zane ... Alabama Health Insurance Exchange . Zane Benefits, which provides ... benefits, is the leader in defined contribution plans ... to Zane Benefits’ website, beginning in 2014 as part ... for individuals and small businesses will become available through ...
Breaking Medicine News(10 mins):Health News:Veterans Disability Appeals See Fewer Decisions in FY2012, Reports Allsup 2Health News:'Boys will be boys' in US, but not in Asia 2Health News:'Boys will be boys' in US, but not in Asia 3Health News:Patricia O’Laughlin Psychotherapy of Los Angeles Now Seeing Adults, Teens and Young Children 2Health News:Handicap This! Comes to Marion, Iowa 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3
... with $150K Donation to the University of Pittsburgh ... After losing a battle to Merkel Cell Carcinoma, an aggressive and deadly ... through a donation by the Al Copeland Foundation to the University ... Copeland Day on June 28, 2009. , , Al Copeland ...
... June 30 Biopure Corporation (Nasdaq: BPUR ) ... by letter dated June 24, 2009, that it is out of ... be delisted. The notice stated that the company no longer ... on the Nasdaq Capital Market. , , Nasdaq advised that ...
... reduced pain and restored mobility in tendinitis patients, study ... of people suffer from tendinitis of the rotator cuff, ... pain and restore mobility of the shoulder, Italian researchers ... tendinitis, which involves small calcium deposits within the tendons ...
... high percentage of women responded favorably to a bioidentical ... , MAPLE GROVE, Minn., June 30 Upsher-Smith ... to determine the response rates to three doses of ... 57th Annual Clinical Meeting of the American College of ...
... SOUTH SAN FRANCISCO, Calif., June 30 Hyperion Therapeutics, ... development of therapies that address critical unmet needs in ... has closed a $60 million Series C financing. New ... financing. Series A and B investors Highland Capital Partners, ...
... the most out of treatment during the summer months and beyond ... the arrival of summer means more time outdoors, with trips to ... more enjoyable than soaking up the sun and having fun with ... actually mean a worsening of symptoms and the need for extra ...
Cached Medicine News:Health News:Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 2Health News:Al Copeland Day Lives on Through Efforts To Cure Merkel Cell Carcinoma 3Health News:Nonsurgical Treatment May Ease Rotator Cuff Injury 2Health News:New Data: Efficacy and Responder Analyses of Divigel(R) (estradiol gel) 0.1 percent for the Treatment of Menopause 2Health News:New Data: Efficacy and Responder Analyses of Divigel(R) (estradiol gel) 0.1 percent for the Treatment of Menopause 3Health News:New Data: Efficacy and Responder Analyses of Divigel(R) (estradiol gel) 0.1 percent for the Treatment of Menopause 4Health News:New Data: Efficacy and Responder Analyses of Divigel(R) (estradiol gel) 0.1 percent for the Treatment of Menopause 5Health News:Hyperion Therapeutics Raises $60 Million Series C 2Health News:Hyperion Therapeutics Raises $60 Million Series C 3Health News:Summertime Sun Exposure Can 'Burn' Acne Sufferers in More Ways than One 2Health News:Summertime Sun Exposure Can 'Burn' Acne Sufferers in More Ways than One 3
... STAARVISC II is a sterile nonpyrogenic, ... hyaluronate. STAARVISC II contains 12 mg/ml of ... daltons) sodium hyaluronate dissolved in physiological saline. ... the viscosity is 105,000 cps (105 Pa ...
The Sonic WAVE™is the first market-ready Alternative to Ultrasound...
... The Stat Profile pHOx series consists of six ... and critical care profiles. Measured tests include pH, ... %, hematocrit, hemoglobin, sodium, potassium, ionized calcium, chloride, ... less than one minute. Its space saving design ...
... compact Sleepscan Traveler provides the ultimate flexibility ... PSG data in the home, a patient ... sleep studies utilize the same powerful Sleepscan ... Sleepscan Traveler studies take full advantage of ...
Medicine Products: